Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5752)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 14, 2024 (publication date) through Dec 17, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Soresi M, Giannitrapani L. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2024; 30(30): 3541-3547 [PMID: 39193573 DOI: 10.3748/wjg.v30.i30.3541] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Soresi M, Giannitrapani L. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2024; 30(30): 3541-3547 [PMID: 39193573 DOI: 10.3748/wjg.v30.i30.3541] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i30/3541.htm |
| Number | Citing Articles |
| 1 |
Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho. Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease. Trends in Endocrinology & Metabolism 2025; 36(11): 1000 doi: 10.1016/j.tem.2025.03.006
|
| 2 |
Adrián Cortés-Martín, Julio Plaza-Diaz. Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders. World Journal of Gastroenterology 2025; 31(4): 101436 doi: 10.3748/wjg.v31.i4.101436
|
| 3 |
Jan Škrha. Liver steatosis and Type 2 diabetes mellitus. Vnitřní lékařství 2025; 71(3): 170 doi: 10.36290/vnl.2025.030
|
| 4 |
Jae Eun So, Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Hye Won Lee, Seung Up Kim. The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease. Journal of Gastroenterology and Hepatology 2025; 40(12): 2976 doi: 10.1111/jgh.70134
|
| 5 |
Alfredo Vozza, Domenico Triggiani, Margherita Fanelli, Giuseppe Lisco, Deborah Coletto, Carlo Custodero, Sara Volpe, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Rosselia Maggipinto, Andrea Portacci, Cosimo Tortorella, Antonio Moschetta, Giuseppina Piazzolla. Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study. Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1674308
|
| 6 |
Shujun Li, Nanqu Huang, Mei Wang, Wendi Huang, Yong Luo, Juan Huang. GLP-1R in diabetes mellitus: from basic discovery to therapeutics development. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1610512
|
| 7 |
Mo-Wei Kong, Yang Yu, Ying Wan, Yu Gao, Chun-Xiang Zhang. Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases. World Journal of Gastroenterology 2024; 30(36): 4036-4043 doi: 10.3748/wjg.v30.i36.4036
|
| 8 |
Junyu Wang, Jingting Lei, Martin C. Harmsen, Han Moshage. From cooperation to collapse: systemic failure in liver disease through a sociological lens. Exploration of Digestive Diseases 2025; 4 doi: 10.37349/edd.2025.100580
|
| 9 |
Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He. Targeting Metabolism: Innovative Therapies for MASLD Unveiled. International Journal of Molecular Sciences 2025; 26(9): 4077 doi: 10.3390/ijms26094077
|
| 10 |
Anmol Singh, Aalam Sohal, Akash Batta. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World Journal of Gastroenterology 2024; 30(48): 5205-5211 doi: 10.3748/wjg.v30.i48.5205
|
| 11 |
Mithil Gowda Suresh, Safia Mohamed, Harinivaas Shanmugavel Geetha, Sushmita Prabhu, Nitin Trivedi, Priyal Dilip Mehta, Udaya Kumar Damodaran, Ajit Brar, Aalam Sohal, Juniali Hatwal, Akash Batta. Cardiovascular Implications in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. Korean Circulation Journal 2026; 56 doi: 10.4070/kcj.2025.0212
|
| 12 |
Yilmaz Gunes. A brief approach to hypertension in type 2 diabetes mellitus. Exploration of Endocrine and Metabolic Diseases 2025; doi: 10.37349/eemd.2025.101422
|
| 13 |
Piotr Olejnik, Kaja Kasarełło, Renata Podkowińska-Polak, Aleksandra Golenia. Psoriasis: an emerging risk factor for ischemic stroke?. Frontiers in Neurology 2025; 16 doi: 10.3389/fneur.2025.1599978
|
| 14 |
Jheng-Yan Wu, Wan-Hsuan Hsu, Chia-Chih Kuo, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Kuo-Chuan Hung, Tsung Yu, Chih-Cheng Lai. A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD. Nature Communications 2025; 16(1) doi: 10.1038/s41467-025-62891-8
|